RT Book, Section
A1 Ursem, Carling
A1 McQuaid, Kenneth R.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193162330
T1 Gastric Adenocarcinoma
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193162330
RD 2024/04/16
AB Key  Clinical  Updates  in  Gastric  AdenocarcinomaTriplet  chemotherapy  for  resectable  gastric  cancer  is  recommended  for  patients  who  are  fit  but  is  associated  with  more  toxicity  than  doublet  chemotherapy.The  development  of  immunotherapy  represents  a  promising  strategy  in  a  selected  patients  with  locally  advanced  and  metastatic  gastric  cancer.  Testing  for  microsatellite  instability-high  (MSI-H),  mismatch  repair  deficiency  (dMMR),  PD-1,  and  PD-L1  is  recommended  in  advanced  disease  to  identify  tumors  that  may  respond  to  immunotherapy.ASGE  Standards  of  Practice  Committee;  Jue  TL  et  al.  Gastrointest  Endosc.  [PMID:  33168194]de  Steur  WO  et  al;  CRITICS  investigators.  Ann  Oncol.  [PMID:  33227408]Kawazoe  A  et  al.  Jpn  J  Clin  Oncol.  [PMID:  33241322]Ng  SP  et  al.  Ann  Surg  Oncol.  [PMID:  33689079]